Everolimus (Votubia®)

Assessment Status Rapid review complete
Drug Everolimus
Brand Votubia®
Indication For the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery
Assessment Process
Rapid review commissioned 30/09/2011
Rapid review completed 14/10/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.